Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02694822
Recruitment Status : Active, not recruiting
First Posted : March 1, 2016
Last Update Posted : July 7, 2021
Sponsor:
Information provided by (Responsible Party):
Agenus Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : October 31, 2021
Estimated Study Completion Date : December 15, 2021